[{"id":"2b64af10-d65b-4d9e-b123-5cd01fb9300a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627063","created_at":"2022-11-25T15:58:10.134Z","updated_at":"2024-07-02T16:35:38.335Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05627063","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK121"],"overall_status":"Recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-09-01"}]